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Neurocysticercosis appears to be on the rise in the United States, based on immigration patterns and pub-
lished cases series, including reports of domestic acquisition. We used a collaborative network of U.S.
emergency departments to characterize the epidemiology of neurocysticercosis in seizure patients. Data
were collected prospectively at 11 university-affiliated, geographically diverse, urban U.S. emergency
departments from July 1996 to September 1998. Patients with a seizure who underwent neuroimaging
were included. Of the 1,801 patients enrolled in the study, 38 (2.1%) had seizures attributable to neurocys-
ticercosis. The disease was detected in 9 of the 11 sites and was associated with Hispanic ethnicity, immi-
grant status, and exposure to areas where neurocysticercosis is endemic. This disease appears to be
widely distributed and highly prevalent in certain populations (e.g., Hispanic patients) and areas (e.g.,
Southwest).
eurocysticercosis is the most common parasitic disease of
the central nervous system. It is endemic in many devel-
oping countries and has been cited as the primary reason that
“epilepsy” is twice as common in these countries as in more
industrialized nations such as the United States (1). The preva-
lence of neurocysticercosis in some of these developing coun-
tries exceeds 10% (2,3), where it accounts for up to 50% of
cases of late-onset epilepsy (4).
International travel and immigration are bringing neuro-
cysticercosis to areas where it is not endemic. Several case
series have been published from a variety of institutions
throughout the United States, especially in the Southwest (5–
10), but none has directly assessed the prevalence of neurocys-
ticercosis. Domestic acquisition of the disease has been docu-
mented not only in large, metropolitan centers that attract large
numbers of immigrants but also in less urban areas of North
and South Carolina (11). Local acquisition has even been dem-
onstrated in such unlikely areas as an Orthodox Jewish com-
munity, where it was attributed to the employment of domestic
workers from Central and South American countries (12).
Seizures are the most frequent, and often the only, clinical
manifestation of neurocysticercosis; they occur in 70% to 90%
of cases (10,13). Because seizure patients frequently go to
emergency departments, we chose this setting to perform a
prospective study to determine the prevalence and epidemiol-
ogy of this disease.
Materials and Methods
This study was a prospective case series of patients who
visited any of a network of 11 geographically diverse, univer-
sity-affiliated, urban emergency departments (EMERGEncy
ID NET) from July 1996 to September 1998. The approximate
total annual visit census of these emergency departments is
900,000. Institutional review board approval for the study was
obtained at all sites. A more detailed description of EMER-
GEncy ID NET, including its administration and the processes
of data transfer and compilation, has been published (14).
Emergency department patients >5 years of age were
enrolled in the study if they had a known or suspected seizure
and had undergone neuroimaging, either computed tomogra-
phy scanning (CT) or magnetic resonance imaging (MRI).
Patients <5 years of age were excluded to avoid enrolling a
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potentially large number of patients with febrile seizures. The
treating physician recorded demographic and clinical data
including age, sex, race, immigrant status, foreign travel, prior
seizure history, seizure type, CT and MRI findings, presump-
tive diagnosis, and disposition. 
When blood was drawn from a patient as part of the evalu-
ation, an additional tube was obtained for this study. Serum
specimens from 890 of the 1,801 patients enrolled were sent to
the Centers for Disease Control and Prevention so that sero-
logic testing for cysticercosis could be performed. Serum sam-
ples were tested by enzyme-linked immunoelectrotransfer blot
for  Taenia solium–specific antibodies, as described (15,16).
Briefly, this assay uses seven purified glycoprotein antigens
from larval cysts of T. solium, namely, GP50, GP42-39, GP24,
GP21, GP18, GP14, and GP13, where the prefix GP stands for
glycoprotein and the number indicates the molecular mass in
kilodaltons. These antigens are used in an immunoblot format
to detect infection-specific antibodies. Reactions to at least
one antigen band are considered positive (15,16).
On the basis of a classification scheme proposed by Del
Brutto (17), our case definition for neurocysticercosis required
either 1) CT scan finding(s) characteristic of neurocysticerco-
sis (i.e., multiple calcifications or multiple cystic lesions) with
or without a positive serologic test, or 2) CT scan finding(s)
consistent with neurocysticercosis (i.e., a single cystic, calci-
fied, or hypodense lesion) and a positive serologic test. Radiol-
ogists at each site read CT scans without regard for or
knowledge of the study. Study coordinators at each site then
abstracted the absence or presence of findings relevant to the
study from the radiology reports. Simple descriptive statistics
were used to summarize the clinical features of patients with
and without neurocysticercosis. Relative risk ratios (RRs) and
their corresponding 95% confidence intervals (CIs) were
determined by Fisher’s exact test.
Results
A total of 1,801 eligible patients with 1,833 emergency
department visits were enrolled during the 2-year study period.
Twenty-eight patients had multiple visits; four patients under-
went evaluation on three separate occasions (Table 1). A
diverse group of seizure patients were enrolled in the study
(Table 2).
From the entire study population, 2.1% (38) patients met
the case definition for neurocysticercosis (Table 3). Of patients
who underwent both CT scanning and serologic testing, 2.9%
met the case definition. Thirty-four patients satisfied the case
definition based on classic CT scan findings, and four satisfied
the case definition based on a positive serologic test coupled
with CT scan findings consistent with neurocysticercosis.
Neurocysticercosis was identified at 9 of the 11 study sites; 6
sites enrolled more than one patient (Table 3). Patients with
this disease tended to be younger than patients who did not
meet the case definition (Table 4). Patients were also more
likely to be Hispanic, have been born outside the United
States, have visited or lived in an endemic region, be unin-
sured, and have a reported history of neurocysticercosis. Over-
all, approximately 9% of patients with Hispanic ethnicity who
came to an emergency room with a seizure met the case defini-
tion for neurocysticercosis. The prevalence of the disease in
the Hispanic patients with seizures ranged from 9% to 13.5%
in the highest risk sites.
Patients meeting the case definition for neurocysticercosis
were not more likely to have a new-onset seizure (versus hav-
ing an established history of seizures; RR 1.1; CI 0.56 to 2.01).
Neurocysticercosis patients were, however, more likely to
have focal motor or partial complex seizures than those with-
out neurocysticercosis (RR 2.6; CI 1.3 to 5.5) (Table 4).
Serologic testing was performed on 49.4% (890) of the
1,801 patients enrolled, and results were positive in 2% (18)
Table 1. Demographic and clinical characteristics of 1,833 neuro-
imaged emergency department seizure patientsa
Characteristics Patients (%)
Sex (male) 1,220 (67)
Race/ethnicity
  Black 753 (41)
  White, non-Hispanic 643 (35)
  Hispanic 320 (17)
  Native American 43 (2.3)
  Asian/Pacific Islander 33 (1.8)
  Other or unknown 41 (2.2)
Insurance
  Medicare/private 462 (25.2)
  Medicaid 391 (21.3)
  Uninsured 762 (41.6)
Immigrant statusb
  Born in USA 820 (61)
  Not born in USA 178 (13)
  Unknown 350 (26)
Exposure to disease-endemic region
  No travel outside USA 950 (51.8)
  Exposure to disease-endemic region 342 (18.7)
  Unknown travel history 541 (29.5)
Seizure type
  Generalized tonic/clonic 1,577 (86)
  Focal motor 114 (6.2)
  Partial complex 86 (4.7)
  Unknown or undocumented 56 (3.1)
Seizure history
  Prior seizure history 810 (44)
  No prior seizure history 896 (49)
  Unknown seizure history 127 (7)
aThe median age (interquartile range) in yrs for these patients was 40 (range 30–51 yrs). 
b1,348 patients; immigrant status data was not collected on the first 485 patients.RESEARCH
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cases. No significant differences were detected in age, seizure
history, seizure type, prior history of neurocysticercosis, immi-
grant status, or exposure to an endemic region between the
patients who underwent serologic testing and those who did
not. Nine of the seropositive patients had CT scan findings
consistent with neurocysticercosis; nine did not. Compared
with the seronegative patients, seropositive patients were more
likely to be Hispanic (RR 8.7; CI 3.1 to 24.1), have visited or
lived in a neurocysticercosis-endemic region (RR 6.8; CI 2.2
to 20.5), and have an abnormal CT scan (RR 1.7; CI 1.2 to
2.3). Seropositivity was not significantly associated with either
new-onset seizures or prior seizure history. Serology was posi-
tive in 27% of the patients who had neuroimaging findings
characteristic of neurocysticercosis, 5.3% of those with consis-
tent neuroimaging findings, and 1.1% of those with neuroim-
aging findings inconsistent with neurocysticercosis.
Seven patients reported a history of neurocysticercosis.
Four (57%) of these patients had neuroimaging findings typi-
cal of or consistent with neurocysticercosis. Serologic testing
was performed on two of the seven patients with one negative
and one positive result.
The use of our case definition identified two patients who
were not diagnosed with neurocysticercosis by the emergency
department physician but who were later clinically diagnosed
with neurocysticercosis. One was a child born in the United
States to Laotian parents whose travel history was unknown;
the other was a man of Hispanic ethnicity whose travel history
and immigration status were not available. On the other hand,
half of the patients diagnosed with neurocysticercosis by their
treating physician did not satisfy our case definition. No con-
firmed cases of domestically acquired neurocysticercosis were
identified during the study period.
Discussion
Immigrants continue to make up an increasing proportion
of the U.S. population. By some reports, they will constitute
up to 60% of the new immigrants and new births over the next
few decades (18,19). By the year 2037, Latinos will outnum-
ber whites as the dominant ethnic group in California, mirror-
ing a population surge that is sweeping across the Southwest
(20). Because neurocysticercosis is endemic in many of the
countries from which these persons are emigrating, its pres-
ence in the United States reflects these immigration trends.
Table 2. Emergency department physicians’ diagnoses for 1,348a 
neuroimaged seizure patients 
Diagnosis Seizure patients (%)
Etiology uncertain 515 (38)
Alcohol or drug abuse/withdrawal 253 (19)
Head injury 105 (7.8)
Epilepsy 92 (6.8)
Otherb 104 (7.7)
Brain tumor 42 (3.1)
Metabolic disorder (e.g., hypoglycemia) 39 (2.9)
Stroke 36 (2.7)
Neurocysticercosis 30 (2.2)
Nontraumatic cerebral hemorrhage 22 (1.6)
Syncope, possibly not seizure 25 (1.9)
Meningitis or brain abscess 18 (1.3)
Pseudoseizure 14 (1.0)
Toxoplasmosis 12 (0.9)
No diagnosis documented 42 (3.1)
aThe method of categorizing discharge diagnoses was modified during the study. These 
data represent the last 1,348 of 1,833 patient encounters.
bOther category includes six patients with recent neurosurgery, three with toxic levels of 
anticonvulsant medications, three with reactions to non-anticonvulsant medication, 
three with systemic lupus erythematosus, and several other less frequently occurring 
causes.
Table 3. Neurocysticercosis and selected demographic characteristics of seizure patients, U.S. sites
Site
Total seizure
patients enrolled
Hispanic patients
enrolled (%)
Immigrants 
enrolleda (%)
Neurocysticercosis patients 
identified (%)
Albuquerque, NM 107 58 (54) 9 (8) 6 (5.6)
Atlanta, GA 146 4 (3) 6 (4) 0 (0.0)
Charlotte, NC 300 11 (4) 17 (6) 4 (1.3)
Kansas City, MO 164 12 (7) 3 (2) 1 (0.6)
Los Angeles, CA 91 52 (57) 21 (23) 9 (9.9)
New Orleans, LA 174 9 (5) 8 (5) 2 (1.1)
New York, NY 184 50 (27) 54 (29) 1 (0.5)
Orlando, FL 68 6 (9) 9 (13) 0 (0.0)
Philadelphia, PA 185 20 (11) 19 (10) 1 (0.5)
Phoenix, AZ 243 90 (37) 27 (11) 10 (4.1)
Portland, OR 171 8 (5) 5 (3) 4 (2.3)
Total 1,833 320 (17) 179 (10) 38 (2.1)
aImmigration data were not obtained from the first 490 patients enrolled.Emerging Infectious Diseases  •  Vol. 8, No. 6, June 2002 611
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Previous etiologic surveys of seizures in the United States
and other industrialized countries have focused on brain
tumors, strokes, and birth defects (21–23). Infections such as
toxoplasmosis and meningitis or meningoencephalitis consti-
tute a small minority of causes in seizure patients. More
recently, HIV and its attendant complications have become
prominent causes of adult-onset seizures (23). Neurocysticer-
cosis, while a prominent cause of seizures in less developed
nations, has not appeared in these studies. 
An increasing number of neurocysticercosis cases (5–10)
have been reported throughout the United States, which sug-
gests that the prevalence of this disease may be on the rise.
Because these previous case series were conducted retrospec-
tively, primarily through chart reviews over periods as long as
a decade, understanding the epidemiology and impact of neu-
rocysticercosis is difficult. To our knowledge, this prospective
study is the first to address the prevalence of neurocysticerco-
sis in seizure patients in the United States.
Neurocysticercosis was identified at 9 of 11 sites and was
responsible for 2.1% of seizures overall. In some sites, e.g.,
Los Angeles, California, and Albuquerque, New Mexico, the
prevalence was nearly 10%. That neurocysticercosis has not
appeared in previous U.S. studies on the epidemiology of sei-
zures and now appears in our study as the cause of up to 10%
of seizures in some areas suggests a substantial increase in fre-
quency of this disease. Another study from a Los Angeles–
area hospital corroborates this finding: 12% of the seizures
seen in the authors’ emergency department were attributable to
neurocysticercosis (24). 
Previous reports on neurocysticercosis in the United
States, mostly retrospective case series, have focused on the
clinical and epidemiologic aspects of the disease (5–10) Those
studies are somewhat limited by the inadequacies and incom-
pleteness inherent in retrospective data collection. It also
seems problematic when epidemiologic information (e.g.,
exposure to a disease-endemic area) constitutes part of the
case definition/inclusion criteria (e.g., exposure to cysticerco-
sis-endemic area) but then epidemiologic information is subse-
quently reported as a result (e.g., percentage of patients who
had visited an area where cysticercosis is endemic). In con-
trast, our data were collected at the time of evaluation, and our
case definition was based solely on clinical criteria. As such,
our study provides additional corroboration to the findings of
previous studies reporting strong associations between neuro-
cysticercosis and Hispanic ethnicity, immigrant status, and
prior exposure to disease-endemic regions. Neurocysticercosis
patients were also more likely to be uninsured; however, lack
of insurance was also associated with being Hispanic and an
immigrant. Consistent with previous studies, most neurocys-
ticercosis patients did come to the emergency department with
a generalized tonic clonic seizure, but such patients were more
likely to have focal motor or partial complex seizures than
were the seizure patients without neurocysticercosis. On the
basis of our results, neurocysticercosis must be strongly
Table 4. Demographic and clinical characteristics of neurocysticercosis 
patientsa and non-neurocysticercosis patients 
Features
Neurocysticer-
cosis patients
n=37 (%)
Non-neurocys-
ticercosis 
patients
n=1,796 (%)
Relative risk
95% CI
Sex, male 27 (73.0) 1,189 (66.0)
Racial/ethnic backgroundb
  Black 4 (10.8) 746 (41.6)
  White, non-Hispanic 3 (8.1) 640 (35.7)
  Hispanic 29 (78.4) 291 (16.2) 17.1 (7.9 to 37.1)
Insurance status
  Medicare/private 7 (18.9) 455 (25.3)
  Medicaid 3 (8.1) 386 (21.5)
  Uninsured 22 (59.5) 738 (41.1) 2.5 (1.2 to 5.2)
Immigrant statusc 
  Born in US 5 (21.0) 815 (62.0)
  Not born in US 12 (50.0) 166 (13.0) 11.1 (3.9 to 31.0)
  Unknown 7 (29.0) 343 (26.0)
Exposure to endemic region
  No travel out of US  0 (0) 950 (52.9)
  Exposure to endemic
  region
28 (75.7) 314 (17.5) 158 (9.7 to 2,581)
  Unknown travel 
   history
9 (24.3) 532 (29.6)
Prior history of neurocysticercosisc 
  Positive prior history 3 (16.0) 5 (0.5) 21.6 (7.8 to 59.8)
  No prior history 16 (84.0) 906 (99.5)
Seizure type
  Generalized 26 (70.3) 1,551 (86.4) 0.38 
(0.18 to 0.80)d
  Tonic/clonic 4
  Focal motor 2 (5.4) 112 (6.2)
  Partial complex 7 (18.9) 79 (4.4)
  Unknown/
  undocumented
2 (5.4) 54 (3.0)
Seizure history
  New onset 19 (51.0) 877 (49.0) 1.1 (0.56 to 2.02)
  Prior seizure history 17 (46.0) 793 (44.0)
Serologic testing
  Seropositive 9 (36.0) 9 (1.0) NAe
  Seronegative 16 (64.0) 856 (99.0)
Disposition
  Admission 16 (43.0) 865 (48.0) 1.0 (0.5 to 2.0)
  Discharge 15 (41.0) 801 (45.0)
aA patient was a person who met the case definition for neurocysticercosis. See text. The 
median age for neurocysticercosis patients was 32 yrs, with a range of 25–44 yrs; the 
median age of non-neurocysticercosis patients was 40 yrs (range 30–52 yrs).
bn = 36 for this category.
cn = 1,343; immigrant status was not collected from the first 490 patients enrolled.
dGeneralized seizure versus focal motor or partial complex seizures.
eNA, not applicable. Comparison was not done since serology was part of the case defini-
tion for neurocysticercosis.
CI, confidence intervals.RESEARCH
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considered in emergency department seizure patients of His-
panic descent since nearly 1 in 10 were affected, a figure that
was even higher in certain areas.
From 1988 through 1990, 7.2% of neurocysticercosis cases
reported to the Los Angeles Department of Health Services
were locally acquired (25). The rate of domestic acquisition
has been even higher (17% to 26%) in some studies of pediat-
ric neurocysticercosis (6,8). These rates of domestic acquisi-
tion appear to have increased from earlier studies in the late
1970s and early 1980s, when the rates were in the range of 2%
to 3%. Because years can pass before symptoms develop, the
incidence of domestically acquired cases will likely continue
to rise.
The apparent increase in the prevalence of neurocysticer-
cosis carries a substantial economic impact. Nearly half of the
seizure patients in our study were admitted to the hospital. The
average cost of hospitalization for seizures in one study was
$1,615 per patient, not including physician charges (26). The
economic toll extends beyond such direct costs. Compared
with the general population, seizure patients are seen in the
emergency departments 2½ times more frequently, admitted to
the hospital 3 times more frequently, and treated by specialists
3 times more frequently; they also receive psychological coun-
seling 7 times more frequently (27) These figures still underes-
timate the true economic impact of neurocysticercosis because
up to 30% of patients who visit an emergency room do not
have seizures but rather a variety of other neurologic symp-
toms such as headache, visual changes, ataxia, and confusion.
Hydrocephalus may develop in a substantial number if
patients, requiring neurosurgical intervention.
Any study of neurocysticercosis is limited by the difficulty
in clearly establishing the diagnosis. The only true measure for
the diagnosis of neurocysticercosis is brain biopsy, which is
clearly impractical. This study therefore implemented a case
definition that incorporates the classification scheme proposed
by Del Brutto (17) but is therefore limited by the predictive
value of CT scan and serology. Serology has previously been
demonstrated to be sensitive in cases with multiple cysts
(94%) but less sensitive with single cysts or calcified lesions
(28%) (28). Specimen storage and periodic bulk mailing may
have further affected intrinsic test performance.
We found a considerable discrepancy between patients
who were diagnosed with neurocysticercosis by their physi-
cians and patients who met our case definition. Because we
did not specifically ask the treating physicians how they
arrived at their diagnosis, the exact reasons for this discrep-
ancy are unclear. However, emergency room physicians
appear to rely considerably on epidemiologic information
when diagnosing neurocysticercosis. Of patients diagnosed by
their physicians, 98% were Hispanic (compared with our 76%)
and 80% were immigrants (compared with our 50%). Ten per-
cent of the patients with physician-diagnosed neurocysticerco-
sis had normal CT scans.
Additional limitations to the study include the fact that the
participating network sites are university-affiliated emergency
departments. This fact may limit the generalizability of our
results to other patient populations. Ideally, serologic testing
would have been performed on all patients, but laboratory test-
ing is not routinely performed for all seizure patients seen in
emergency departments. Patients who did undergo serologic
testing were, however, not statistically different from those
who did not, on the basis of the demographic information col-
lected.
In summary, while neurocysticercosis accounts for a small
proportion (2.1%) of all seizures in university-affiliated, U.S.
emergency department patients, its geographic distribution
appears diverse; the highest concentration is in the Southwest
and in Hispanics. Our observations are consistent with current
immigration trends that suggest the growing importance of
neurocysticercosis in the United States. Continued surveil-
lance and further studies of screening and treatment strategies
appear warranted.
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